Motor signs during the course of Alzheimer disease

Neurology

Volumn 63, Issue 6, 2004, Pages 975-982

  Scarmeas, N ^a,e,f   Hadjigeorgiou, G M ^e   Papadimitriou, A ^e   Dubois, B ^d   Sarazin, M ^d   Brandt, J ^b   Albert, M ^c   Marder, K ^a   Bell, K ^a   Honig, L S ^a   Wegesin, D ^a   Stern, Y ^a  

^a NewYork Presbyterian Hospital   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF THESSALY   (Greece)

^f New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; BRADYKINESIA; COVARIANCE; DISEASE COURSE; FEMALE; GAIT; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM;

EID: 4644295335     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000138440.39918.0C     Document Type: Article

References (49)

1. Miller TP, Tinklenberg JR, Brooks JO 3rd, Yesavage JA. Cognitive decline in patients with Alzheimer disease: differences in patients with and without extrapyramidal signs. Alzheimer Dis 1991;5:251-256.
2. Kraemer HC, Tinklenberg J, Yesavage JA. "How far" vs "how fast" in Alzheimer's disease. The question revisited. Arch Neurol 1994;51:275-279.
3. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994:51:676-681.
4. Drachman DA, O'Donnell BF, Lew RA, Swearer JM. The prognosis in Alzheimer's disease. "How far" rather than "how fast" best predicts the course. Arch Neurol 1990;47:851-856.
5. Soininen H, Laulumaa V, Helkala EL, Hartikainen P, Riekkinen PJ. Extrapyramidal signs in Alzheimer's disease: a 3-year follow-up study. J Neural Transm 1992;4:107-119.
6. Lopez OL, Wisnieski SR, Becker JT, Boller F, DeKosky ST. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 1997;54:969-975.
7. Burns A, Jacoby R, Levy R. Neurological signs in Alzheimer's disease. Age Ageing 1991;20:45-51.
8. Samson WN, van Duijn CM, Hop WC, Hofman A. Clinical features and mortality in patients with early-onset Alzheimer's disease. Eur Neurol 1996;36:103-106.
9. Van Dijk PT, Dippel DW, Van Der Meulen JH, Habbema JD. Comorbidity and its effect on mortality in nursing home patients with dementia. J Nerv Ment Dis 1996;184:180-187.
10. Mitchell SL, Rockwood K. The association between parkinsonism, Alzheimer's disease, and mortality: a comprehensive approach. J Am Geriatr Soc 2000;48:422-425.
11. Murman DL, Kuo SB, Powell MC, Colenda CC. The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology 2003;61:944-949.
12. Ellis RJ, Caligiuri M, Galasko D, Thai LJ. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alzheimer Dis 1996;10:103-114.
13. Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA. Progression of parkinsonian signs in Alzheimer's disease. Neurology 2000;54:1284-1289.
14. Stern Y, Folstein M, Albert M, et al. Multicenter study of predictors of disease course in Alzheimer disease (the "Predictors Study"). I. Study design, cohort description, and intersite comparisons. Alzheimer Dis 1993;7:3-21.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
16. Stern Y, Sano M, Paulson J, Mayeux R. Modified Mini-Mental State Examination: validity and reliability. Neurology 1987;37(suppl 1):179.
17. Hixson JE. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb 1991;11:1237-1244.
18. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology 1981;31:645-650.
19. Wechsler D. Wechsler Adult Intelligence Scale Revised. New York: Psychological Corp., 1981.
20. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia: Lea & Febiger, 1983.
21. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
22. Richards M, Marder K, Bell K, Dooneief G, Mayeux R, Stern Y. Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol 1991;48:1147-1149.
23. Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology 1997;49:1580-1587.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
25. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrica 1986;73:13-22.
26. Lawless J. Statistical model and methods for lifetime data. New York: Wiley, 1982.
27. Chen JY, Stern Y, Sano M, Mayeux R. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease. Arch Neurol 1991;48:1141-1143.
28. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999;56:334-337.
29. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein epsilon 4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997;41:615-620.
30. Scarmeas N, Brandt J, Albert M, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology 2002;58:1182-1188.
31. Nielsen AS, Ravid R, Kamphorst W, Jorgensen OS. Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders. J Alzheimers Dis 2003;5:119-125.
32. Hansen LA, Galasko D, Samuel W, Xia Y, Chen X, Saitoh T. Apolipoprotein-E epsilon-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. Neurosci Lett 1994;182:63-65.
33. Olichney JM, Hansen LA, Galasko D, et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996;47:190-196.
34. Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987;37:754-760.
35. Joachim CL, Morris JH, Selkoe DJ. Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann Neurol 1988;24:50-56.
36. Haan MN, Jagust WJ, Galasko D, Kaye J. Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease. Arch Neurol 2002;59:588-593.
37. Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998;51:351-357.
38. Heyman A, Fillenbaum GG, Gearing M, et al. Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX. Neurology 1999;52:1839-1844.
39. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22:911-922.
40. Weiner MF, Risser RC, Cullum CM, et al. Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases. Am J Psychiatry 1996;153:1269-1273.
41. Stern Y, Jacobs D, Goldman J, et al. An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol 2001;58:460-465.
42. Reinikainen KJ, Paljarvi L, Halonen T, et al. Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging 1988;9:245-252.
43. Snowden MB, Bowen JD, Hughes J, Larson EB. Study of Alzheimer's dementia patients with parkinsonian features. J Geriatr Psychiatry Neurol 1995;8:154-158.
44. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? Arch Neurol 1989;46:651-657.
45. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 1995;37:300-312.
46. Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Markakis D. Striatal dopamine receptors in Alzheimer-type dementia. Neurosci Lett 1984;52:1-6.
47. Tyrrell PJ, Sawle GV, Ibanez V, et al. Clinical and positron emission tomographic studies in the "extrapyramidal syndrome" of dementia of the Alzheimer type. Arch Neurol 1990;47:1318-1323.
48. Rothschild D, Kasanin J. Clinicopathologic study of Alzheimer's disease. Arch Neurol Psychiatry 1936;36:293-321.
49. Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 1997;41:368-374.